Annexin Pharmaceuticals

Executive Summary

Annexin Pharmaceuticals is a Swedish clinical-stage biotechnology company advancing ANXV, a recombinant human Annexin A5 protein, as a first-in-class therapeutic targeting phosphatidylserine (PS) exposed on stressed or damaged cells. This mechanism addresses inflammation, coagulation, and immune evasion, with broad therapeutic potential. The company is currently focused on two lead indications: Retinal Vein Occlusion (RVO) in ophthalmology and oncology. ANXV has demonstrated promising preclinical and early clinical data, positioning it as a potential novel treatment for vascular and inflammatory diseases. With a strong intellectual property portfolio and a clear clinical development path, Annexin aims to address significant unmet medical needs in these high-value indications.

Upcoming Catalysts (preview)

• H2 2026Phase 2 RVO data readout40% success
• Q4 2026Initiation of Phase 1/2 oncology trial50% success
• H2 2026Potential partnership or licensing deal30% success